CD79A and shigellosis: Placebo subjects not progressing to shigellosis were found to have significantly higher LPS-specific IgA+ BM cell responses on the day of challenge as compared to placebos who developed shigellosis, confirming the protective role of LPS-specific IgA+ BM cell responses that was also reported in the 53G CHIM study described above.